Guoqin Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Guoqin Jiang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Liyan Jin
Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
2 shared publications Yanlin Gu
Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
2 shared publicationsKaiming Liu
Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication- Ren-Gen Fan
Department of General Surgery, Yancheng First Hospital,Affiliated Hospital of Nanjing University Medical School (The First people’s Hospital of Yancheng), Yancheng 224006, Jiangsu Province, China
1 shared publication Wen-Zhang Zha
Yancheng City No. 1 People's Hospital
1 shared publicationXiaoyan Xu
Department of Operating Room Traditional Chinese Medicine Hospital of Kunshan Kunshan China
1 shared publication
Latest Publications
- 2 February 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (7) , 2931-2944
Integrative analysis of SEC13: a prognostic predictor and immunotherapeutic target
Background The SEC13 is a multifaceted gene implicated in mTORC1 signaling regulation and the maintenance of genomic stability. Its function in cancer is complex, displaying potential oncogenic as well as potential tumor-suppressive roles across different malignancies. Therefore, this study aimed to investigate SEC13 expression, prognostic value, and its relationship with immune checkpoints across different cancer types. Methods Differential expression analysis, diagnostic analysis, and prognostic analysis were analyzed with The Cancer Genome Atlas and Human Protein Atlas database. The potential related genes were analyzed by utilizing Gene Expression Omnibus and clinical breast cancer samples. GO (Gene Ontology) and GSEA (Gene Set Enrichment Analysis) were used to elucidate the potential role of SEC13. TMB (tumor mutation burden), MSI (microsatellite instability), immune checkpoint, and immune cell infiltration were also analyzed to indicate its potential role in immune feature. To validate the functional impact of SEC13, its effects on cell proliferation and cell cycle distribution were assessed using CCK-8 assays and flow cytometry in MDA-MB-231 and MCF7 breast cancer cells following SEC13 knockdown. Results SEC13 was highly expressed in 14 tumor types and lowly expressed in 2 tumor types. High expression of SEC13 was associated with worse overall survival, disease-specific survival, and progression-free interval in breast cancer, liver hepatocellular carcinoma, and sarcoma. SEC13 expression was correlated with several co-expressed genes (e.g., MED8, RPN1) and was enriched in cell cycle pathway. Functionally, SEC13 knockdown was found to reduce the S-phase cell proportion and inhibit cell proliferation. In addition, SEC13 exhibited relationships with TMB and MSI, immune checkpoint, and immune cell infiltration. Conclusion This study underscores the significant expression differences and prognostic implications of SEC13 in various cancers, emphasizing its potential as a biomarker and therapeutic target.
- 2 February 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (7) , 2931-2944
Integrative analysis of SEC13: a prognostic predictor and immunotherapeutic target
Background The SEC13 is a multifaceted gene implicated in mTORC1 signaling regulation and the maintenance of genomic stability. Its function in cancer is complex, displaying potential oncogenic as well as potential tumor-suppressive roles across different malignancies. Therefore, this study aimed to investigate SEC13 expression, prognostic value, and its relationship with immune checkpoints across different cancer types. Methods Differential expression analysis, diagnostic analysis, and prognostic analysis were analyzed with The Cancer Genome Atlas and Human Protein Atlas database. The potential related genes were analyzed by utilizing Gene Expression Omnibus and clinical breast cancer samples. GO (Gene Ontology) and GSEA (Gene Set Enrichment Analysis) were used to elucidate the potential role of SEC13. TMB (tumor mutation burden), MSI (microsatellite instability), immune checkpoint, and immune cell infiltration were also analyzed to indicate its potential role in immune feature. To validate the functional impact of SEC13, its effects on cell proliferation and cell cycle distribution were assessed using CCK-8 assays and flow cytometry in MDA-MB-231 and MCF7 breast cancer cells following SEC13 knockdown. Results SEC13 was highly expressed in 14 tumor types and lowly expressed in 2 tumor types. High expression of SEC13 was associated with worse overall survival, disease-specific survival, and progression-free interval in breast cancer, liver hepatocellular carcinoma, and sarcoma. SEC13 expression was correlated with several co-expressed genes (e.g., MED8, RPN1) and was enriched in cell cycle pathway. Functionally, SEC13 knockdown was found to reduce the S-phase cell proportion and inhibit cell proliferation. In addition, SEC13 exhibited relationships with TMB and MSI, immune checkpoint, and immune cell infiltration. Conclusion This study underscores the significant expression differences and prognostic implications of SEC13 in various cancers, emphasizing its potential as a biomarker and therapeutic target.
- Open Access
- 25 November 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (22) , e70227
LINC01929 Is a Prognostic Biomarker for Multiple Tumours and Promotes Cell Proliferation in Breast Cancer Through the TNF/STAT3 Axis
The aim of this study was to investigate whether long intergenic non‐coding RNA 1929 (LINC01929), a novel long non‐coding RNA, could serve as a prognostic biomarker for various tumours and explore its function. The expression and prognosis of LINC01929 across 33 different tumour types in patients in the Cancer Genome Atlas (TCGA) database were analysed. Also, the correlation between LINC01929 expression, tumour mutational burden (TMB), microsatellite instability (MSI), immune checkpoint status and immune cell infiltration was examined. Moreover, the function of LINC01929 in the breast cancer cell lines was explored via CCK‐8, colony formation and cell cycle assays. In addition, the downstream mechanisms of LINC01929 were analysed via transcriptome sequencing, RT–qPCR, and western blotting. Our analysis revealed that LINC01929 was weakly expressed in 3 tumour types and highly expressed in 14 tumour types, and low expression of LINC01929 was correlated with better clinical outcomes in 15 tumour types. Furthermore, LINC01929 expression was correlated significantly with the TMB, MSI, immune checkpoint and immune cell infiltration across multiple tumour types. The knockdown of LINC01929 inhibited cell cycle progression, cell proliferation, and tumorigenesis and downregulated the TNF pathway and STAT3 expression. The treatment with exogenous TNF‐α partially reversed the cell cycle progression and proliferation inhibition caused by LINC01929 knockdown, and these effects were accompanied by changes in STAT3 expression. LINC01929 may serve as an effective biomarker affecting the TMB, MSI, immune cell infiltration and immune checkpoint status. Mechanistically, LINC01929 affects cell cycle progression and cell proliferation through the TNF/STAT3 axis. These findings offer valuable insights into the potential applications of LINC01929 in tumour therapy, which may yield novel targets and strategies for the diagnosis and treatment of patients.
- 25 November 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (22) , e70227
Open AccessLINC01929 Is a Prognostic Biomarker for Multiple Tumours and Promotes Cell Proliferation in Breast Cancer Through the TNF/STAT3 Axis
The aim of this study was to investigate whether long intergenic non‐coding RNA 1929 (LINC01929), a novel long non‐coding RNA, could serve as a prognostic biomarker for various tumours and explore its function. The expression and prognosis of LINC01929 across 33 different tumour types in patients in the Cancer Genome Atlas (TCGA) database were analysed. Also, the correlation between LINC01929 expression, tumour mutational burden (TMB), microsatellite instability (MSI), immune checkpoint status and immune cell infiltration was examined. Moreover, the function of LINC01929 in the breast cancer cell lines was explored via CCK‐8, colony formation and cell cycle assays. In addition, the downstream mechanisms of LINC01929 were analysed via transcriptome sequencing, RT–qPCR, and western blotting. Our analysis revealed that LINC01929 was weakly expressed in 3 tumour types and highly expressed in 14 tumour types, and low expression of LINC01929 was correlated with better clinical outcomes in 15 tumour types. Furthermore, LINC01929 expression was correlated significantly with the TMB, MSI, immune checkpoint and immune cell infiltration across multiple tumour types. The knockdown of LINC01929 inhibited cell cycle progression, cell proliferation, and tumorigenesis and downregulated the TNF pathway and STAT3 expression. The treatment with exogenous TNF‐α partially reversed the cell cycle progression and proliferation inhibition caused by LINC01929 knockdown, and these effects were accompanied by changes in STAT3 expression. LINC01929 may serve as an effective biomarker affecting the TMB, MSI, immune cell infiltration and immune checkpoint status. Mechanistically, LINC01929 affects cell cycle progression and cell proliferation through the TNF/STAT3 axis. These findings offer valuable insights into the potential applications of LINC01929 in tumour therapy, which may yield novel targets and strategies for the diagnosis and treatment of patients.
- Open Access
- 1 January 2018
- Published by Sociedad Espanola de Patologia Digestiva (SEPD) in Revista Española de Enfermedades Digestivas
- Vol. 111 (3) , 176-181
A two-stage versus single-stage procedure for the management of cholecysto-choledocholithiasis in elderly patients: a retrospectively cohort study
There is an increasing incidence rate of cholecysto-choledocholithiasis associated with the increasing proportion of senile individuals. a total of 100 elderly patients (over 80 years of age) suffering both from cholelithiasis and choledocholithiasis were retrospectively studied from January 2010 to December 2016. Patients were scheduled for either a single-stage or two-stage procedure. The LCBDE group (n = 54) included cases that underwent a single stage procedure of laparoscopic exploration of the common bile duct combined with cholecystectomy. The ERCP/EST group (n = 46) included cases that underwent a two stage procedure of preoperative endoscopic retrograde cholangiopancreaticography with endoscopic sphincterotomy followed by cholecystectomy. Comorbidity conditions, presenting symptoms, bile duct clearance, length of hospital stay and the frequency of procedural, postoperative and long-term complications were recorded. the LCBDE group had a higher stones clearance rate than the ERCP/EST group (100.0% vs 89.1%, p < 0.05). Postoperative complications and hospitalization length were comparable in the two groups (p > 0.05). There were more procedural complications in the ERCP/EST group than in the LCBDE group (10.8% vs 0%, p < 0.05). Furthermore, a patient in the ERCP/EST group died due to duodenal perforation. More patients in the ERCP/EST group experienced long-term complications than those in the LCBDE group (23.9% vs 3.7%, p < 0.05) during a mean follow-up period of 28.4 months. the single-stage procedure is a safe and effective technique for elderly patients with cholecysto-choledocholithiasis. LCBDE provides a good stone clearance rate with few long term complications.
- 1 January 2018
- Published by Sociedad Espanola de Patologia Digestiva (SEPD) in Revista Española de Enfermedades Digestivas
- Vol. 111 (3) , 176-181
Open AccessA two-stage versus single-stage procedure for the management of cholecysto-choledocholithiasis in elderly patients: a retrospectively cohort study
There is an increasing incidence rate of cholecysto-choledocholithiasis associated with the increasing proportion of senile individuals. a total of 100 elderly patients (over 80 years of age) suffering both from cholelithiasis and choledocholithiasis were retrospectively studied from January 2010 to December 2016. Patients were scheduled for either a single-stage or two-stage procedure. The LCBDE group (n = 54) included cases that underwent a single stage procedure of laparoscopic exploration of the common bile duct combined with cholecystectomy. The ERCP/EST group (n = 46) included cases that underwent a two stage procedure of preoperative endoscopic retrograde cholangiopancreaticography with endoscopic sphincterotomy followed by cholecystectomy. Comorbidity conditions, presenting symptoms, bile duct clearance, length of hospital stay and the frequency of procedural, postoperative and long-term complications were recorded. the LCBDE group had a higher stones clearance rate than the ERCP/EST group (100.0% vs 89.1%, p < 0.05). Postoperative complications and hospitalization length were comparable in the two groups (p > 0.05). There were more procedural complications in the ERCP/EST group than in the LCBDE group (10.8% vs 0%, p < 0.05). Furthermore, a patient in the ERCP/EST group died due to duodenal perforation. More patients in the ERCP/EST group experienced long-term complications than those in the LCBDE group (23.9% vs 3.7%, p < 0.05) during a mean follow-up period of 28.4 months. the single-stage procedure is a safe and effective technique for elderly patients with cholecysto-choledocholithiasis. LCBDE provides a good stone clearance rate with few long term complications.